Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 232 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombotic Disease Clear all
Completed No phase listed Observational

Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants

NCT02604420
View directory record Official record
Conditions
Thrombotic Microangiopathy, Disorder Related to Bone Marrow Transplantation
Interventions
eculizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 23, 2026, 2:26 PM EDT
Completed No phase listed Observational

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NCT02014896
View directory record Official record
Conditions
Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke of Basilar Artery, Cardioembolic Stroke
Interventions
Biomarker blood draw
Other
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Sacramento, California • San Francisco, California • Detroit, Michigan + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 23, 2026, 2:26 PM EDT
Terminated No phase listed Observational

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

NCT01386723
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Discontinuation of eltrombopag
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

NCT01071954
View directory record Official record
Conditions
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Interventions
Romiplostim
Biological
Lead sponsor
Amgen
Industry
Eligibility
1 Year and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
24
States / cities
Orange, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome

NCT02148029
View directory record Official record
Conditions
Acute Deep Vein Thrombosis
Interventions
Exercise, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00411801
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
Uniplas, Cryosupernatant plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Centreville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 23, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

NCT00220727
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

NCT00844844
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

NCT01143038
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Romiplostim
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

NCT04669600
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP)
Interventions
SAR445088 (BIVV020)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tamarac, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 23, 2026, 2:26 PM EDT
Completed No phase listed Observational

Deep Venous Thrombus Characteristics and Venous Dynamics With Subsequent Thrombus Resolution and Post-thrombotic Syndrome

NCT04597138
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

NCT04409834
View directory record Official record
Conditions
COVID-19, Venous Thromboembolism, Arterial Thrombosis
Interventions
Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel, Unfractionated heparin SC, Enoxaparin 40 mg SC
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 23, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04200456
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04687072
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Springdale, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00908037
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 23, 2026, 2:26 PM EDT
Active, not recruiting Not applicable Interventional

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

NCT05035823
View directory record Official record
Conditions
Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Spinal Cord Injuries, Stroke, Lacunar, Stroke Brainstem, Cervical Spinal Cord Injury, Spinal Muscular Atrophy, Tetraplegic; Paralysis, Quadriplegia/Tetraplegia
Interventions
Motor Neuroprosthesis (MNP)
Device
Lead sponsor
Synchron Medical, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Buffalo, New York • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

NCT02923115
View directory record Official record
Conditions
Pulmonary Embolism, Thrombotic Disease
Interventions
DS-1040b, Placebo, Enoxaparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 23, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

NCT01707394
View directory record Official record
Conditions
Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
18
States / cities
Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 23, 2026, 2:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

NCT01087333
View directory record Official record
Conditions
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 2:26 PM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 23, 2026, 2:26 PM EDT
Completed No phase listed Observational Results available

Novel Biomarkers of Thrombotic Risk

NCT02505217
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 23, 2026, 2:26 PM EDT